去纤苷在国内是否上市？

On October 22, 2013, it was approved for marketing by the European Union as the first treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation.

On March 30, 2016, the U.S. Food and Drug Administration (FDA) approved defibrotide for the treatment of hepatic veno-occlusive disease (VOD) caused by hematopoietic stem cell transplantation in adults and children with renal and pulmonary dysfunction.

Defibrotide is the first and only drug for the treatment of severe hepatic veno-occlusive disease. Is defibrotide available on the market in China?

According to Medical Companion Travel, defibrotide has not yet been officially launched in mainland China, but it has been launched abroad. The price of defibrotide listed abroad is about 22,000. Due to the floating exchange rate, the price is different. Please consult Medical Companion Travel for the specific price!

Defibrotide is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects.

Defibrotide can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells.

Defibrinoside Dosage and Administration:

Administer defibrotide 6.25 mg/kg every 6 hours as a 2-hour intravenous infusion. Treatment lasts for a minimum of 21 days. If the signs and symptoms of VOD do not resolve after 21 days. Continue treatment until resolution.

Contraindications to defibrotide:

1. Simultaneous administration with systemic anticoagulants or fibrinolytic therapy;

2. Known hypersensitivity to defibrotide or any excipient.

In addition, the most common adverse reactions (incidence ≥10% and independent causal relationship) with treatment were hypotension, diarrhea, vomiting, nausea and epistaxis.

Recommended related hot articles: /newsDetail/74955.html